Human Genome Sciences, GlaxoSmithKline report positive results in 2nd lupus drug studyNovember 2nd, 2009 Human Genome reports positive data on lupus drugNEW YORK — Human Genome Sciences and GlaxoSmithKline said Monday their experimental lupus treatment passed another key goal on its path to potentially becoming the first new drug for the disease in decades. Shares of Human Genome Sciences soared more than 35 percent on the report.
Botox shot can relieve chronic pain in peopleOctober 26th, 2009 WASHINGTON - Botox is more than just a solution to beat wrinkles. It can even be used as a pain medication to fight Chronic Regional Pain Syndrome (CRPS), according to a new study.
Epilepsy drug could raise schizophrenia riskOctober 21st, 2009 WASHINGTON - Researchers at Georgetown University Medical Center have found that antiepilectic drug treatments administered when the brain is developing could trigger schizophrenia-like behaviour. A history of seizures during infancy leaves a person at significantly higher risk of developing schizophrenia later in life, but researchers aren't sure whether the seizures themselves or the drugs used to treat them are to blame.
FDA clears Glaxo's long-delayed vaccine Cervarix, creating new competition for MerckOctober 16th, 2009 FDA approves Glaxo's cervical cancer vaccineWASHINGTON — GlaxoSmithKline said Friday U.S. regulators approved its vaccine Cervarix to prevent the leading cause of cervical cancer in women, following a two-year delay.
Depomed says its post-shingles pain drug succeeded it trial, and shares hit three-year highOctober 5th, 2009 Depomed says shingles pain drug meets study goalMENLO PARK, Calif. — Depomed Inc.
FDA advisers unanimously back GlaxoSmithKline drug for kidney cancer, despite liver risksOctober 5th, 2009 FDA panel unanimously backs Glaxo cancer drugGAITHERSBURG, Md. — Federal health advisers said Monday an experimental kidney cancer drug from GlaxoSmithKline PLC can benefit patients by slowing the disease, despite some risk of liver damage.
FDA notes liver damage risks with GlaxoSmithKline's kidney cancer drugOctober 1st, 2009 FDA questions safety of Glaxo kidney cancer drugWASHINGTON — Federal regulators said Thursday an experimental kidney cancer drug from GlaxoSmithKline may cause liver problems, potentially outweighing its ability to slow the disease. London-based Glaxo wants the Food and Drug Administration to approve its pazopanib pills for advanced kidney cancer, a rare but deadly form of the disease.
Drug combo better than individual medications for treating chronic painOctober 1st, 2009 WASHINGTON - A combination of two commonly prescribed drugs offers a much more effective treatment for people with debilitating neuropathic pain than if they take either of the medications individually, according to a study by Queen's University researchers. When given both an anti-seizure drug (gabapentin) and an antidepressant (nortriptyline), patients suffering from neuropathic pain caused by nerve damage or disease experienced less pain than when they took one or the other individually, reports Dr.
FDA delays decision on GlaxoSmithKline's cervical cancer vaccine CervarixSeptember 30th, 2009 FDA delays ruling on Glaxo cervical cancer vaccineWASHINGTON — The Food and Drug Administration has delayed a decision on GlaxoSmithKline's vaccine for cervical cancer, according to the British drugmaker. The FDA was scheduled to announce its ruling Tuesday on whether to approve Cervarix, but a Glaxo spokeswoman said the review will continue.
Institute of Medicine will review FDA's system for clearing low-risk medical devicesSeptember 23rd, 2009 FDA medical device approvals get external reviewWASHINGTON — The Food and Drug Administration is asking the government's top medical advisers to review its system for approving certain types of medical devices that has been criticized by safety advocates and government watchdogs. The Institute of Medicine will study FDA's so-called 510k review procedure, which allows device companies to immediately launch products similar to those already on the market.
Adolor buys rights to Eli Lilly drug, plans studies on opioid bowel dysfunctionSeptember 21st, 2009 Adolor buys rights to Eli Lilly drugEXTON, Pa. — Biotechnology company Adolor Corp.
GlaxoSmithKline, Xenoport report positive midstage study results from potential pain drugSeptember 17th, 2009 Glaxo, Xenoport report positive pain drug studyNEW YORK — GlaxoSmithKline and Xenoport Inc. said Thursday their developing neuropathic pain treatment candidate met its key goal of lowering pain intensity in a midstage study.
WHO should revise TB treatment guidelines, say scientistsSeptember 15th, 2009 WASHINGTON - French and American scientists have recommended that the World Health Organization (WHO) must review, and adjust its guidelines for the fight against tuberculosis (TB). TB is a global threat that affects more than 10 million people each year.
Electrical nerve stimulation may relieve neuropathic pain after spinal cord injurySeptember 12th, 2009 WASHINGTON - A new study has revealed that electrical nerve stimulation can effectively reduce neuropathic pain following a spinal cord injury. Neuropathic pain is often difficult to relieve and usually managed with drugs such as antidepressants or anticonvulsants.
FDA says GlaxoSmithKline vaccine blocks virus that causes most cervical cancers in womenSeptember 4th, 2009 FDA says Glaxo vaccine blocks cancer-causing virusWASHINGTON — A vaccine from GlaxoSmithKline successfully blocks the virus that causes most cases of cervical cancer, the Food and Drug Administration said Friday. In documents posted online, the FDA said Cervarix — Glaxo's vaccine against human papilloma virus or HPV — successfully blocked the two most cancerous strains of the virus nearly 93 percent of the time.
